Emergent BioSolutions Reports Second Quarter 2026 Financial Results
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Wed, 5 August 2026
What it is about
Substipharm BiologicsStephanie DuatschekJoe PapaDavis SchneiderBusiness DevelopmentTerms Of ServiceBc Take Home Naloxone ProgramCompany WinnipegServices SalesDevelopment ExpensesUnited StatesGlobal Strategy Franchise DevelopmentSingapore Health Sciences AuthorityNational Naloxone Awareness DayEmergent Biosolutions IncDrug Authority ApprovalSingaporeCanadaBritishCanadian
Who published it, and when
How it spread - 1 original report
Wed, 5 August 2026
1 report- manilatimes.net20:29first to report
Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash impairment chargeSecond Quarter 2026 Adjusted Net Income of $30.9 million improved 134% versus prior yearSecond Quarter 2026 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 1400 bps and 900 bps, respectively, versus prior yearSecond Quarter 2026 Adjusted...